CD28 individual signals amplify pro-inflammatory cytokine production in relapse-remitting multiple sclerosis T lymphocytes
Loretta
Tuosto1, 2*,
Michela
Muscolini1,
Cristina
Camperio1,
Elisabetta
Volpe3,
Rosella
Mechelli3, 4,
Serena
Ruggieri4, 5,
Marco
Salvetti4,
Claudio
Gasperini5 and
Luca
Battistini3
-
1
Sapienza University, Department of Biology and Biotechnology C. Darwin, Italy
-
2
Istituto Pasteur-Fondazione Cenci Bolognetti, Italy
-
3
IRCCS Santa Lucia, Neuroimmunology Unit, Italy
-
4
S. Andrea Hospital, Sapienza University, Neurology and Centre for Experimental Neurological Therapies, Italy
-
5
S Camillo Forlanini Hospital, Department of Neurosciences, Italy
CD28 may be considered one of the most important costimulatory receptor that by binding its cognate ligands B7.1/CD80 or B7.2/CD86 on the surface of professional antigen presenting cells (APCs), lowers TCR activation threshold and leads to the augmentation of early signalling events necessary for efficient cytokine production, cell cycle progression and survival. The role of CD28 in multiple sclerosis (MS) has been often evaluated as the source of costimulatory signals integrating those delivered by TCR and blockade of CD28/B7 interaction by recombinant CTLA4-Ig, which binds B7 molecules with high affinity, is being evaluated for the use in MS patients. However, CD28 is also able to act as a unique signalling receptor and to arise TCR-independent autonomous signals. We have previously demonstrated that CD28 stimulation by agonistic antibodies or B7 expressed on APCs, in the absence of TCR engagement, is able to activate a specific NF-κB pathway in peripheral CD4+ T cells, leading to both the production of pro-inflammatory cytokine/chemokines and to the activation of survival genes.. NF-κB has been defined as a central mediator of the immune responses, by regulating the expression of over 150 genes including chemokines, cytokines and adhesion molecules involved in inflammation. Thus, CD28 stimulation may provide TCR-independent signals, which sustain the inflammatory response in MS.
By comparing the cytokine and chemokine patterns of peripheral blood CD4+ T cells isolated from relapsing-remitting MS (RRMS) patients and healthy donors (HD), we found that in RRMS but not in HD, CD28 stimulation selectively induces the expression of IL-6, IL-21 and IL-17A, all cytokines related to the Th17 cell profile phenotype. We also demonstrate that the up-regulation of all pro-inflammatory cytokines tested was dependent on CD28-mediated phosphatydilinositol 3 kinase (PI3K) activation. Therefore,CD28 could be considered as a novel receptor molecule that may contribute to amplify the inflammatory response in RRMS by favouring pro-inflammatory cytokine production and Th17 amplification.
Acknowledgements
This work was supported by Fondazione Italiana Sclerosi Multipla-FISM-Cod. 2011/R/36 (Genova, Italy)
Keywords:
Multiple Sclerosis,
T lymphocytes,
Inflammation,
CD28,
Th17 Cells,
PI3K
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Immune-mediated disease pathogenesis
Citation:
Tuosto
L,
Muscolini
M,
Camperio
C,
Volpe
E,
Mechelli
R,
Ruggieri
S,
Salvetti
M,
Gasperini
C and
Battistini
L
(2013). CD28 individual signals amplify pro-inflammatory cytokine production in relapse-remitting multiple sclerosis T lymphocytes.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00627
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
12 Jun 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Prof. Loretta Tuosto, Sapienza University, Department of Biology and Biotechnology C. Darwin, Rome, 00185, Italy, loretta.tuosto@uniroma1.it